Ernexa Therapeutics Inc. Noncash or Part Noncash Acquisition, Debt Assumed
Ernexa Therapeutics Inc. (ERNA) reported Noncash or Part Noncash Acquisition, Debt Assumed of $1.70 million for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-17.
Discontinued › Cash Flow › Operating Activities
us-gaap:NoncashOrPartNoncashAcquisitionDebtAssumed1 · last filed 2021-05-17
- Ernexa Therapeutics Inc. noncash or part noncash acquisition, debt assumed for the quarter ending 2021-03-31 was $1.70M.
- Ernexa Therapeutics Inc. noncash or part noncash acquisition, debt assumed for the quarter ending 2020-03-31 was $0.00.
| Period end | Noncash or Part Noncash Acquisition, Debt Assumed 3 month |
|---|---|
| 2021-03-31 | $1.70M 10-Q · filed 2021-05-17 |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |